These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 37789267)

  • 1. ARPC5 acts as a potential prognostic biomarker that is associated with cell proliferation, migration and immune infiltrate in gliomas.
    Ming Y; Luo C; Ji B; Cheng J
    BMC Cancer; 2023 Oct; 23(1):937. PubMed ID: 37789267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma.
    Huang S; Sun L; Hou P; Liu K; Wu J
    Front Immunol; 2022; 13():944898. PubMed ID: 36148220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Prognostic Analysis of Immune Implication Value and Oxidative Stress Significance of NECAP2 in Low-Grade Glioma.
    Lu Z; Chen Y; Chen S; Zhu X; Wang C; Wang Z; Yao Q
    Oxid Med Cell Longev; 2022; 2022():1494520. PubMed ID: 36531205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
    Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
    Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic prediction and immune checkpoint profiling in glioma patients through neddylation-associated features.
    Qi J; Li L; Gao B; Dai K; Shen K; Wu X; Li H; Yu Z; Wang Z; Wang Z
    Gene; 2024 Dec; 930():148835. PubMed ID: 39127414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGIF2 is a potential biomarker for diagnosis and prognosis of glioma.
    Zhang W; Zhang L; Dong H; Peng H
    Front Immunol; 2024; 15():1356833. PubMed ID: 38629068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of PIMREG in the prognosis and response to immune checkpoint blockade of glioma patients.
    Zhu H; Hu X; Feng S; Gu L; Jian Z; Zou N; Xiong X
    Front Immunol; 2022; 13():946692. PubMed ID: 35928818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
    Li J; Zhang Y; Qu Z; Ding R; Yin X
    Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
    Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
    Front Oncol; 2021; 11():611038. PubMed ID: 33937022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Arp2/3 Complex Subunits as Prognostic Biomarkers for Hepatocellular Carcinoma.
    Huang S; Li D; Zhuang L; Sun L; Wu J
    Front Mol Biosci; 2021; 8():690151. PubMed ID: 34307456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PROS1 shapes the immune-suppressive tumor microenvironment and predicts poor prognosis in glioma.
    Wang J; Wu N; Feng X; Liang Y; Huang M; Li W; Hou L; Yin C
    Front Immunol; 2022; 13():1052692. PubMed ID: 36685506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Single-cell transcriptome analysis of multigrade glioma heterogeneity and immune microenvironment revealed potential prognostic biomarkers].
    Liu J; Xu K; Ma L; Wang Y
    Sheng Wu Gong Cheng Xue Bao; 2022 Oct; 38(10):3790-3808. PubMed ID: 36305410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel prognostic biomarker TBC1D1 is associated with immunotherapy resistance in gliomas.
    Song D; Yang Q; Li L; Wei Y; Zhang C; Du H; Ren G; Li H
    Front Immunol; 2024; 15():1372113. PubMed ID: 38529286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ARPC5 is transcriptionally activated by KLF4, and promotes cell migration and invasion in prostate cancer via up-regulating ADAM17 : ARPC5 serves as an oncogene in prostate cancer.
    Qu G; Zhang Y; Duan H; Tang C; Yang G; Chen D; Xu Y
    Apoptosis; 2023 Jun; 28(5-6):783-795. PubMed ID: 36881291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
    Hong X; Zhang J; Zou J; Ouyang J; Xiao B; Wang P; Peng X
    Cell Signal; 2023 Feb; 102():110560. PubMed ID: 36521657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-1908 as a novel prognosis marker of glioma via promoting malignant phenotype and modulating SPRY4/RAF1 axis.
    Chai Z; Fan H; Li Y; Song L; Jin X; Yu J; Li Y; Ma C; Zhou R
    Oncol Rep; 2017 Nov; 38(5):2717-2726. PubMed ID: 29048686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
    Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
    Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL4I1 in M2-like macrophage promotes glioma progression and is a promising target for immunotherapy.
    Ye F; Wang L; Li Y; Dong C; Zhou L; Xu J
    Front Immunol; 2023; 14():1338244. PubMed ID: 38250074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.